RenovoRx (RNXT) Total Liabilities (2020 - 2026)
RenovoRx (RNXT) posted Total Liabilities of $2.7 million for Q1 2026, up 0.97% sequentially from $2.7 million in Q4 2025, and down 5.53% YoY from $2.9 million in Q1 2025.
RenovoRx (RNXT) Total Liabilities (2020 - 2026) Analysis & Trends
RenovoRx has reported Total Liabilities for 7 years, with the latest figure at $2.7 million in Q1 2026.
- Quarterly Total Liabilities fell 5.53% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 5.53% YoY) and the FY2025 annual result came in at $2.7 million, down 26.57% from the prior year.
- Total Liabilities climbed to $2.7 million in Q1 2026 per RNXT's latest filing, from $2.7 million in the prior quarter.
- Over five years, Total Liabilities peaked at $5.1 million in Q2 2023 and troughed at $1.1 million in Q3 2022.
- A 5-year average of $2.7 million and a median of $2.9 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities surged 356.46% in 2023, then slumped 46.7% in 2024.
- Over 5 years, Total Liabilities stood at $1.1 million in 2022, then surged by 305.26% to $4.5 million in 2023, then decreased by 18.5% to $3.6 million in 2024, then retreated by 26.57% to $2.7 million in 2025, then increased by 0.97% to $2.7 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.7 million, $2.7 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | 2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.49 Mn |
| Mar 31, 2026 | 2.70 Mn |
| Dec 31, 2025 | 2.67 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Mar 31, 2024 | 3.02 Mn |
| Dec 31, 2023 | 4.47 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 5.13 Mn |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | 938,000.00 |
| Sep 30, 2021 | 625,000.00 |